MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 298-304

  Cappuzzo, Federico ^a   Janne P A ^b   Skokan, M ^c   Finocchiaro, G ^a   Rossi, E ^d   Ligorio, C ^a   Zucali, P A ^a   Terracciano, L ^e   Toschi, L ^b   Roncalli, M ^f   Destro, A ^a   Incarbone, M ^a   Alloisio, M ^a   Santoro, A ^a   Varella Garcia, M ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d CINECA   (Italy)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

EGFR; Gefitinib; MET; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR; GEFITINIB; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 60549110433     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn635     Document Type: Article

References (35)

1. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
2. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
4. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
5. Cappuzzo F, Ligorio C, Janne PA et al. Prospective study of gefitinib in EGFR FISH positive/P-Akt positive or never smoker patients with advanced non-small cell lung cancer (NSCLC): The ONCOBELL trial. J Clin Oncol 2007; 25: 2248-2255.
6. She QB, Solit D, Basso A et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′ - kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340-4346.
7. Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822.
8. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207.
9. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: E17.
10. Massarelli E, Varella-Garcia M, Tang X et al. Kras mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
11. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
12. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
13. Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M-mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-6501.
14. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
15. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
16. Ma PC, Maulik G, Christensen J et al. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-325.
17. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26.
18. Ichimura E, Maeshima A, Nakajima T et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 1063-1069.
19. Tsao MS, Liu N, Chen JR et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998; 20: 1-16.
20. Masuya D, Huang C, Liu D et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 1555-1562.
21. Kong-Beltran M, Seshagiri S, Zha J et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66: 283-289.
22. Kuniyasu H, Yasui W, Kitadai Y et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227-232.
23. Tsujimoto H, Sugihara H, Hagiwara A et al. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997; 431: 383-389.
24. Hara T, Ooi A, Kobayashi M et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-1153.
25. Miller CT, Lin L, Casper AM et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006; 25: 409-418.
26. Zhao X, Weir BA, LaFramboise T et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005; 65: 5561-5570.
27. Birchmeier C, Birchmeier W, Gherardi E et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
28. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007; 67: 2081-2088.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-481.
30. Cai T, Moskowitz CS. Semi-parametric estimation of the binomial ROC curve for a continuous diagnostic test. Biostatistics 2004; 5: 573-586.
31. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
32. Wang SE, Narasanna A, Perez-Torres M et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
33. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354: 2619-2621.
34. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-2449.
35. Yang CH, Yu CJ, Shih JY et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745-2753.